Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.79 HKD | -2.86% | -5.03% | +1.65% |
15/04 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
15/04 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.65% | 620M | |
+32.36% | 695B | |
+26.51% | 568B | |
-4.40% | 361B | |
+19.46% | 330B | |
+3.50% | 283B | |
+16.87% | 239B | |
+8.07% | 204B | |
-7.73% | 198B | |
+8.62% | 168B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- UBS Adjusts Ocumension Therapeutics’ Price Target to HK$15.90 From HK$23.20, Keeps at Buy